Antimicrobial Susceptibility Testing<<Return to Search Results
Accredited by the Standards Council of Canada to Laboratory no. 594 (ISO/IEC 17025)
Antimicrobial susceptibility testing of Neisseria gonorrhoeae using the agar dilution method. Antimicrobials on the testing panel include: penicillin, spectinomycin, tetracycline, erythromycin, ceftriaxone, ciprofloxacin, cefixime, gentamicin, ertapenem and azithromycin.
Pure Neisseria gonorrhoeae cultures can be transported in: i) Amies Clear Agar Gel Transport Swabs; ii) Chocolate Agar Slants that have been incubated at 35oC in a CO2 enriched atmosphere for 18-24 hours before transport; iii) BHI (Brain Heart Infusion) broth containing 20% glycerine, frozen at -80oC, shipped on dry ice. Cultures MUST be shipped before the Wednesday of each week.
Shipping of specimens shall be done by a TDG certified individual in accordance with TDG regulations. For additional information regarding classification of specimens for the purposes of shipping, consult either Part 2 Appendix 3 of the TDG Regulations or section 3.6.2 of the IATA Dangerous Goods Regulations as applicable.
For additional guidance on the transport of infectious substances in other languages, please click on the link below.
Infection with N. gonorrhoeae.
Completed Gonococcal Antimicrobial Surveillance Program (GASP) –Canada requisition form with sender lab name, address and telephone number. All patient information must be filled out including patient identifier (specimen reference #), date of birth and sex, type of specimen submitted, date collected, isolation site and test requested. Test results to be included, if possible, are antimicrobial susceptibility values and beta-lactamase results. Urgent specimens must be stated as such on the requisition.
This test is done as part of the Gonococcal Antimicrobial Surveillance Program–Canada (GASP-Canada) testing algorithm.
See CLSI guidelines (2).
180 calendar days. Outbreak associated or urgent isolates will be granted priority status and completed as soon as possible. *Turn around times may not be guaranteed when isolates are submitted in large batches.
- Brown LB, Krysiak R, Kamanga G, Mapanje C, Kanyamula H, Banda B, Mhango C, Hoffman M, Kamwendo D, Hobbs M, Hosseinipour M, Martinson F, Cohen MS, Hoffman IF. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010;37:169-172
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
- Ehret JM, Nims LJ, Judson FN. A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. Sex Transm Dis 1996;23:270-272.
- Daly CC, Hoffman I, Hobbs M, Maida M, Zimba D, Davis R, Mughogho G, Cohen MS. Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: Comparison of methods. J Clin Micro 1997;35:2985-2988.
- Laboratory Protocols for Testing N. gonorrhoeae - Preparation of Antimicrobial Containing Media to Determine Susceptibility of Neisseria gonorrhoeae (Agar Dilution Method) - October 1996 (edited and prepared by M. Pauzé, Bureau of Microbiology)
- Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009;63:1142-1151.
- World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. 2012. Available from: http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/. Accessed 22 May 2012.